Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial


Warning: Array to string conversion in /var/www/vhosts/dev2.tgtherapeutics.com/httpdocs/wp-content/plugins/document-library-pro/dependencies/barn2/document-library-core/src/Document.php on line 665

Warning: Array to string conversion in /var/www/vhosts/dev2.tgtherapeutics.com/httpdocs/wp-content/plugins/document-library-pro/dependencies/barn2/document-library-core/src/Document.php on line 665
Drug Category: Array
Conference Category: Array
Lead Author: Sharman, Burke et al.
Published Date: 21/02/2017
Download Link: https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14447
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top